In Vivo caught up with Benedikt von Braunmühl at the recent BIO-Europe conference in Munich, Germany, to discuss his first six weeks as CEO at Rentschler Biopharma and the biggest trends impacting contract development and manufacturing organizations (CDMO).

This Month's Profile Group: Medtech Start-Ups Innovate in Urinary Incontinence features profiles of Floelle, InControl Medical, NexHand, and Solace Therapeutics. Plus these Start-Ups Across Health Care: Ablative Solutions, Epiomed Therapeutics, Halo Healthcare, and Thrombolytic Science International.

Thrombolytic Science International LLC’s drug candidate for acute post-stroke therapy is a mutant of pro-urokinase, a natural enzyme found in humans that, like tPA, also activates plasmin. TSI’s modified protein is designed to hold its inert, pro-enzymatic form longer in the bloodstream, enabling it to retain its occlusive clot specificity at higher, therapeutic doses with reduced risk of bleeding.